Canaccord lowered the firm’s price target on AxoGen (AXGN) to $24 from $26 and keeps a Buy rating on the shares. The firm updated its model to reflect Q125 results and the subsequent 10Q release. As a reminder, the company reiterated FY25 revenue and gross margin guidance on its Q125 call.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXGN: